A batch of key monitored varieties are intensively collected

On October 25, the website of centralized procurement of drugs and medical consumables of Qinghai Province released the announcement of the results of the proposed candidates for centralized procurement of drugs in 2019, with the publicity period from October 25, 2019 to October 31, 2019 The results of 2019 drug centralized purchase proposed to be shortlisted released by Qinghai Province mainly include key monitoring drugs and basic infusion, and the price of key monitoring drugs is the most concerned As early as September 2, Qinghai Province required monosialotetrahexosylganglioside sodium injection, oxiracetam capsule, cerebrosine and carnosine injection, sodium phosphocreatine for injection, calf serum deproteinization injection, alprostadil injection, troxerutin cerebroprotein hydrolysate injection, compound coenzyme for injection, Danshen chuangongzine injection, invert sugar electrolyte injection, thymus five Peptide injection, edaravone injection, vinpocetine injection, cinepazide maleate injection and other key monitoring varieties, fill in the lowest price in China On October 18, Qinghai Province issued another notice on negotiation of key monitored varieties According to the notice, negotiation was carried out on September 24, mainly in the form of face-to-face negotiation or negotiation between experts and authorized persons of bidding enterprises According to the query of saibelan, Qinghai province carried out centralized procurement with volume for key monitored drugs, mainly based on the implementation plan for centralized procurement and use of drugs in 2019 issued by the people's Government of Qinghai Province at the end of July 2019 According to the sabilan comparison, the centralized drug purchase program in Qinghai Province mainly draws on the experience of centralized drug purchase and use pilot organized by the state However, three types of drugs are included in the scope of centralized drug purchase in Qinghai Province, including the national key monitoring drugs It is clearly mentioned in the plan that "drugs with large quantity and high purchase amount shall be purchased Based on the list of key monitoring drugs published by the national health and Health Commission, the procurement catalogue shall be formulated and centralized bidding procurement shall be carried out " The forms of centralized purchase for the key monitored drugs are as follows: according to the number of enterprises shortlisted for each drug, the corresponding centralized purchase methods are adopted respectively: Among them, if there are less than 3 shortlisted enterprises, the way of negotiation or purchase shall be adopted, and the expert group shall negotiate or negotiate with the shortlisted production enterprises When negotiating or negotiating, the expert group, in combination with the indications and functional efficacy of the drug, demonstrates whether it is clinically necessary Referring to the lowest provincial purchase price in China, the expert group negotiates and negotiates with the enterprise to reach an agreement on the shortlist and the rejected bid without an agreement It can be seen that, after the release of the 2019 drug centralized purchase plan in Qinghai Province, up to now, the centralized purchase of key monitored drugs has gone through four stages: finding the lowest price, issuing the negotiation notice, negotiating with enterprises, and publicizing the results of the proposed selection Although the important premise of drug centralized purchase is to link the quantity and price and exchange the quantity for the price, the price reduction effect is not obvious for the centralized purchase of key monitoring drugs from the perspective of the selected results According to the comparison of cypress blue, the difference between the price after negotiation and the lowest price declared by the enterprise before is not big Many varieties won the bid at the original price, even if some products are reduced in price, the decrease is not big This phenomenon, compared with the first round of 4 + 7 drug collection, has a maximum of 96% and an average of 52%, which is quite different However, it is undeniable that the centralized purchase of key monitored drugs in Qinghai province still has a certain impact on the local market For example, the price negotiation results of the key monitored varieties show that only 50 products are selected and alternative products, and there are still many enterprises with high prices It is worth noting that, even for the key monitored drugs, Qinghai's plan still points out that through bidding, bargaining, negotiation and other different forms of winning the bid, the provincial public medical institutions must give priority to the purchase and use of drugs, and shall not use the total cost, "drug proportion", the requirements of basic drug varieties, specifications and quantity of medical institutions, the review of pharmaceutical Committee and the distribution enterprises are not opened The purchase and rational use of the winning drugs will be affected by the reasons of customers As for the centralized procurement of key monitoring drugs in Qinghai Province, some industry authoritative experts who do not want to be named said to sabilan that there is a slight deviation from the big industry trend, and the reasons behind it cannot be analyzed In fact, experts in the industry have been quite controversial on the issue of centralized purchase of key monitoring drugs According to cypress blue, some well-known experts in the industry think that the most necessary thing for the key monitoring drugs is to limit the dosage, rather than to reduce the price of centralized purchase, because their use should not be encouraged Even with the increase of the varieties included in the centralized drug purchase program of national organizations, in addition to the consistency evaluation of three varieties, these included varieties also need to have a feature that is clinically necessary and indispensable Looking back, although drug collection has been carried out, the price of key monitored varieties has not been reduced effectively The reasons behind this may be traced First, the market volume, i.e the limited volume, and the lack of price reduction power of relevant enterprises Second, many key monitored varieties are exclusive, and the market competition among enterprises is not fierce From 4 + 7 to 25 varieties, different prices have been reduced It can also be seen that the competition among enterprises is an important driving force to promote drug price reduction Even if the mechanism has been established, not all drugs have given a large drop as they wish In this regard, Guo Taihong, the former president of Zhejiang Pharmaceutical Industry Association, told saibelan that the current centralized purchase of medical insurance bureau does not use the administrative forced price reduction of the former health and Family Planning Commission, but "independent bidding, bid evaluation and price comparison, rule confirmation and pricing", which is a price formation mechanism Therefore, it is normal to reduce prices and increase prices, and how much to reduce prices and increase prices, all in line with the market law Bidding is suitable for general drugs, mainly price reduction Negotiation is suitable for drugs with virtual high and virtual low: drugs with virtual high must be lack of competition, so negotiation is needed to exchange quantity for price; drugs with virtual low must be drugs with price lower than cost caused by competition, and drugs with shortage must be negotiated, so supply must be guaranteed by price and quantity must be guaranteed by price.